ATE533783T1 - Potente und selektive mittlersubstanzen von cholesterolefflux - Google Patents

Potente und selektive mittlersubstanzen von cholesterolefflux

Info

Publication number
ATE533783T1
ATE533783T1 AT07874411T AT07874411T ATE533783T1 AT E533783 T1 ATE533783 T1 AT E533783T1 AT 07874411 T AT07874411 T AT 07874411T AT 07874411 T AT07874411 T AT 07874411T AT E533783 T1 ATE533783 T1 AT E533783T1
Authority
AT
Austria
Prior art keywords
cholesterolefflux
potent
polypeptides
apo
parallels
Prior art date
Application number
AT07874411T
Other languages
English (en)
Inventor
John K Bielicki
Jan Johansson
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California filed Critical Univ California
Application granted granted Critical
Publication of ATE533783T1 publication Critical patent/ATE533783T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT07874411T 2006-12-13 2007-12-13 Potente und selektive mittlersubstanzen von cholesterolefflux ATE533783T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US87490906P 2006-12-13 2006-12-13
PCT/US2007/087477 WO2008115303A2 (en) 2006-12-13 2007-12-13 Potent and selective mediators of cholesterol efflux

Publications (1)

Publication Number Publication Date
ATE533783T1 true ATE533783T1 (de) 2011-12-15

Family

ID=39766652

Family Applications (1)

Application Number Title Priority Date Filing Date
AT07874411T ATE533783T1 (de) 2006-12-13 2007-12-13 Potente und selektive mittlersubstanzen von cholesterolefflux

Country Status (11)

Country Link
US (1) US8987192B2 (de)
EP (1) EP2121746B1 (de)
JP (1) JP2010513311A (de)
CN (1) CN101675072A (de)
AT (1) ATE533783T1 (de)
AU (1) AU2007349237B2 (de)
CA (1) CA2672131C (de)
DK (1) DK2121746T3 (de)
ES (1) ES2377329T3 (de)
HK (1) HK1138292A1 (de)
WO (1) WO2008115303A2 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2009260024A1 (en) 2008-06-18 2009-12-23 The Regents Of The University Of California Improved peptide mediators of cholesterol efflux
EP2517013A4 (de) * 2009-12-23 2013-07-17 Artery Therapeutics Inc Diagnose und behandlung von erkrankungen im zusammenhang mit defizientem reversem cholesterintransport
WO2011139819A2 (en) * 2010-04-28 2011-11-10 The Regents Of The University Of California Creation of oxidation-resistant hdl mimetic peptides
US10017551B2 (en) 2013-03-15 2018-07-10 The Regents Of The University Of California Peptides having reduced toxicity that stimulate cholesterol efflux
WO2016044177A1 (en) * 2014-09-17 2016-03-24 The Regents Of The University Of California Peptides having reduced toxicity that stimulate cholesterol efflux
CN112442114A (zh) * 2019-08-29 2021-03-05 渥太华Hdl药物研发公司 一种多肽及其应用
CN112511569B (zh) * 2021-02-07 2021-05-11 杭州筋斗腾云科技有限公司 网络资源访问请求的处理方法、系统及计算机设备

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2367955C (en) 1999-03-15 2009-05-19 University Of British Columbia Abc1 polypeptide and methods and reagents for modulating cholesterol levels
CA2405870A1 (en) * 2000-04-06 2001-10-18 Kos Pharmaceuticals, Inc. Compounds and methods for lowering cholesterol levels without inducing hypertriglyceridemia
US7199102B2 (en) 2000-08-24 2007-04-03 The Regents Of The University Of California Orally administered peptides synergize statin activity
US6664230B1 (en) * 2000-08-24 2003-12-16 The Regents Of The University Of California Orally administered peptides to ameliorate atherosclerosis
WO2005058938A2 (en) 2003-12-15 2005-06-30 The Regents Of The University Of California Helical synthetic peptides that stimulate cellular cholesterol efflux
JP5048486B2 (ja) * 2004-07-16 2012-10-17 トラスティーズ オブ タフツ カレッジ アポリポタンパク質ａ１の模倣物とその使用
US8541236B2 (en) 2006-12-08 2013-09-24 University Of Washington Mutant apolipoprotein A-1 polypeptide with increased resistance to oxidation and reactive carbonyls

Also Published As

Publication number Publication date
EP2121746B1 (de) 2011-11-16
CN101675072A (zh) 2010-03-17
ES2377329T3 (es) 2012-03-26
CA2672131C (en) 2016-06-07
US8987192B2 (en) 2015-03-24
US20120329703A1 (en) 2012-12-27
CA2672131A1 (en) 2008-09-25
JP2010513311A (ja) 2010-04-30
HK1138292A1 (en) 2010-08-20
AU2007349237B2 (en) 2014-01-23
DK2121746T3 (da) 2012-03-05
WO2008115303A2 (en) 2008-09-25
WO2008115303A3 (en) 2008-12-24
EP2121746A2 (de) 2009-11-25
AU2007349237A1 (en) 2008-09-25

Similar Documents

Publication Publication Date Title
ATE533783T1 (de) Potente und selektive mittlersubstanzen von cholesterolefflux
WO2009155366A3 (en) Improved peptide mediators of cholesterol efflux
BRPI0506771A (pt) anticorpo, e, composição farmacêutica
DE60219419D1 (de) Flt4 (vegfr-3) als ein ziel für krebs darstellung und anti-krebs-behandlung
WO2006053315A3 (en) Methods and compositions for treating cellular proliferative diseases
WO2005095457A3 (en) Immunoglobulins
EP1993560A4 (de) Cannabinoid-rezeptor-antagonisten / inverse agonisten zur behandlung von übergewicht
WO2007076055A3 (en) Compositions and methods comprising proteinase activated receptor antagonists
WO2006124748A3 (en) Multicyclic compounds and methods of their use
WO2007135571A3 (en) Blood group antigens of different types for diagnostic and therapeutic applications
WO2008034016A3 (en) Assays for detecting native-state proteins and identifying compounds that modulate the stability of native-state proteins
WO2006096487A3 (en) Methods and compositions for modulating tweak and fn14 activity
NO20082699L (no) Immunoglobuliner
WO2006076736A3 (en) Methods for modulating angiogenesis, lymphangiogenesis, and apoptosis with apelin compositions
WO2007059341A3 (en) Pyrazolothiazole protein kinase modulators
WO2011003100A3 (en) Compositions and methods for diagnosing and/or treating influenza infection
WO2007111982A3 (en) Methods for treating cognitive and other disorders
WO2007067737A3 (en) Methods and compositions for inhibiting hiv infection
WO2007034490A3 (en) Diastereomeric peptides for modulating t cell immunity
WO2004111089A3 (en) Platelet glycoprotein ib alpha variant fusion polypeptides and methods of use thereof
WO2006129867A3 (en) ENHANCED EXPRESSION OF LACTOFERRIN mRNA BY LACRITIN
WO2003038130A8 (en) Therapeutics and diagnostics for disorders of erythropoiesis
WO2005094159A3 (en) Methods of identifying neoplasm-specific antibodies and uses thereof
WO2011139819A3 (en) Creation of oxidation-resistant hdl mimetic peptides
WO2021024133A3 (en) Biopharmacuetical compositions and related methods